EARLY EVALUATION OF LIPOSOMAL DAUNORUBICIN (DAUNOXOME(R), NEXSTAR) INTHE TREATMENT OF RELAPSED AND REFRACTORY LYMPHOMA

We have treated 19 patients with relapsed or refractory lymphoma with liposomally encapsulated daunorubicin (DaunoXome) at two dose schedule s; 40 mg/m(2) repeated every 14 days and 120 mg/m(2) repeated every 21 days. Non-haematological toxicity was mild, in particular, no patient treated with the higher dose schedule showed clinical deterioration i n cardiac function. At the lower dose (10 patients) no objective respo nses were seen but at the higher dose (9 patients) one complete respon se and two partial responses were achieved. Liposomal daunorubicin at 120 mg/m(2) appears to have some activity against refractory lymphoma and we suggest that further studies with this agent are required.